Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
Vancouver, British Columbia (Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (
Entheon or the
Company ) is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (
HaluGen ), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual s reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common shares in the capital of HaluGen (the
HaluGen Shares ) from the shareholders of HaluGen (the
HaluGen Shareholders ) pursuant to a share exchange agreement among the Company, HaluGen and the HaluGen Shareholders, resulting in HaluGen becoming a wholly-owned subsidiary of Entheon (the